Navigating Chronic GVHD: Phases of Pathophysiology and Best Practices in Patient Monitoring

EP: 1.Differentiating Acute and Chronic Graft-vs-Host Disease

Now Viewing

EP: 2.Navigating Chronic GVHD: Phases of Pathophysiology and Best Practices in Patient Monitoring

EP: 3.Optimizing Chronic GVHD Therapy

EP: 4.Navigating Treatment Decisions in Chronic GVHD

EP: 5.Overview of Advanced Therapies in cGVHD

EP: 6.Overview of the ROCKstar Study

EP: 7.Considerations for Third-Line Treatment in Chronic GVHD

EP: 8.Clinical Scenario: Treatment Selection in the third line and beyond in cGVHD

EP: 9.Recent Updates: REACH3, ROCKstar, and RWD

EP: 10.AGAVE-201: Axatilimab for cGVHD

EP: 11.Emerging Trends in Chronic GVHD: Promising Clinical Trials and the Future Treatment Landscape

EP: 12.Clinical Impact of Patient-Reported Outcomes in cGVHD

EP: 13.Multidisciplinary Approaches to GVHD

Video content above is prompted by the following:

• Dr Holtan: Please address the 3 phases of pathophysiology of cGVHD (early inflammation, chronic inflammation and dysregulated immunity, and aberrant repair and fibrosis) and the interplay between them.

How does inflammation affect different organs? And fibrosis?

• Dr Ali:After confirmed diagnosis, please share your monitoring routine for patients with cGVHD.
  • Are there certain symptom scores (eg, Lee skin symptom score) that are associated with better clinical outcomes?
  • How do you share responsibility across subspecialty to monitor patients? Or other HCPS?